ADAGENE INC - ADS, EACH REPRESENTING 1.25
ADAGENE INC - ADS, EACH REPRESENTING 1.25
Depository Receipt · US0053291078 · ADAG · A2QN45 (XNAS)
Overview
1,88 USD
-5,53 % -0,11 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
09.06.2025 19:59

Current Prices from ADAGENE INC - ADS, EACH REPRESENTING 1.25

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
ADAG
USD
09.06.2025 19:59
1,88 USD
1,99 USD
-5,53 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
-5,53 % -9,83 % 17,87 % -9,18 % -8,52 % -36,91 % -93,73 %

Company Profile for ADAGENE INC - ADS, EACH REPRESENTING 1.25 Depository Receipt

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Company Data

Name ADAGENE INC - ADS, EACH REPRESENTING 1.25
Company Adagene Inc.
Symbol ADAG
Website https://www.adagene.com
Primary Exchange XNAS NASDAQ
WKN A2QN45
ISIN US0053291078
Asset Class Depository Receipt
Sector Healthcare
Industry Biotechnology
CEO Dr. Peter P. Luo Ph.D.
Market Capitalization 54 Mio
Country China
Currency USD
Employees 0,1 T
Address Building C14, 215123 Suzhou
IPO Date 2021-02-09

Ticker Symbols

Name Symbol
Frankfurt 978.F
NASDAQ ADAG

More Shares

Investors who ADAGENE INC - ADS, EACH REPRESENTING 1.25 hold also have the following shares in their portfolio:
DZ BANK CLN E.9735
DZ BANK CLN E.9735 Bond
US TREASURY 2021    15.11
US TREASURY 2021 15.11 Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025